Comparison
Mazdutide vs. Retatrutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
2259884-03-0
2381089-83-2
Molecular weight
4790 g/mol
4731.6 g/mol
Half-life
132 h
144 h
Sequence
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteY-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSMechanism of action
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
4
4
Effects recorded
4
4
Open conflicts
0
1
Documented adverse events
0
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Mazdutide and Retatrutide?
- Mazdutide is classified as "Metabolic", while Retatrutide is classified as "Metabolic". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Mazdutide or Retatrutide?
- The highest available evidence level is "Human RCT" for Mazdutide and "Human RCT" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Mazdutide and Retatrutide in Germany and the United States?
- Germany: Mazdutide — Research only, Retatrutide — Unapproved. United States: Mazdutide — Research only, Retatrutide — Unapproved. These are factual summaries with source and review date on the individual pages.